Best Plasmid DNA CDMOs in Asia

← All Plasmid DNA CDMOs Best Clean FDA History Commercial Scale

Region: USA Europe Asia

CDMOs tracked

Fully scored

With FDA records

FDA inspections

For Asia-manufactured plasmid dna programs, Pharmaron Biologics, uBriGene Biosciences, and CoJourney Inc. lead CDMO Signal's ranking of plasmid dna CDMOs with confirmed Asian manufacturing sites. Filtered from the global directory of 23 scored plasmid dna CDMOs to 4 with Asia-Pacific facility presence. Asian CDMOs cover a range of regulatory jurisdictions — PMDA (Japan), NMPA (China), MFDS (South Korea), CDSCO (India) — each with distinct requirements. For sponsors supplying US and EU markets, cross-jurisdictional regulatory posture (FDA and EMA/MHRA inspection history on Asian facilities) is typically the qualifying signal. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.

Plasmid DNA is the upstream starting material for viral vectors, mRNA, and DNA therapeutics — which makes plasmid supply a frequent bottleneck for the entire advanced-therapy pipeline. Plasmid CDMOs run microbial (E. coli) fermentation, alkaline lysis, and chromatographic purification to GMP grade.

Selecting a plasmid CDMO turns on GMP vs research grade, supercoiled fraction and purity, fermentation scale, and lead time. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 3 NAI (no action), 0 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (3).

Last updated 2026-08-01. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

#	CDMO	Signal Score	Quality	FDA · GMP	Capacity	Programs
1	PB Pharmaron Biologics San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China	86.9	100.0	3 insp · 0 GMP	Available	0 programs
2	UB uBriGene Biosciences Shanghai, CN · Boston, MA	60.5	—	—	—	0 programs
3	CoJourney Inc. Horsham, PA (US HQ); Hangzhou, China (primary GMP manufacturing)	60.0	—	—	Limited	0 programs
4	HX Helixmith Seoul, KR	59.0	—	—	—	0 programs
—	BioCina Adelaide, Australia	Profiled	—	—	—	0 programs
—	ARCALIS, Inc. Minamisoma, Fukushima, Japan	Profiled	—	—	—	0 programs
—	EirGenix Zhubei City, Taiwan	Profiled	—	—	—	0 programs
—	AsymBio Shanghai, China	Profiled	—	—	—	0 programs
—	Southern RNA Brisbane, Australia	Profiled	—	—	—	0 programs
—	IDT Australia Boronia, Australia	Profiled	—	—	—	0 programs
—	Canton Biologics Co., Ltd. Foshan (Shunde District), China	Profiled	—	—	—	0 programs
—	Canton Biologics Guangzhou, China	Profiled	—	—	—	0 programs

How we score CDMOs →

What to evaluate in a Plasmid DNA CDMO

GMP grade & purity

Confirm GMP (vs research/HQ) grade, supercoiled percentage, and residual host-cell DNA/RNA and endotoxin specs — these gate downstream vector and mRNA quality.

Fermentation scale & yield

Match fermentation scale and yield to your vector or mRNA demand. Ask about high-yield strains and whether scale-up is validated.

Lead time

Plasmid is a common critical-path bottleneck. Evaluate realistic queue and turnaround against your program timeline.

Regulatory track record

Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

Regulatory landscape across PMDA (Japan), NMPA (China), MFDS (South Korea)

Asian biopharma manufacturing spans multiple national regulators. PMDA (Japan) is generally regarded as one of the most stringent in Asia, with GMP requirements broadly aligned with FDA and EMA. NMPA (China) has substantially strengthened its GMP framework over the past decade, and Chinese CDMOs increasingly hold FDA and EMA certifications alongside NMPA registration. MFDS (South Korea) certification is standard for Korean CDMOs. For sponsors supplying US or EU markets, the qualifying signal for an Asian CDMO is typically FDA and EMA inspection history on the specific facility — which the Signal Score's Quality Compliance pillar captures directly.

Which Asian CDMOs cover FDA (US) and EMA/MHRA (Europe) regulatory geographies?

Asian CDMOs with US FDA and European EMA/MHRA inspection history are qualified to supply global markets; those without cross-jurisdictional inspection posture are typically limited to their home-market regulatory scope. The Signal Score's Quality Compliance pillar includes FDA + EMA + MHRA data directly, so Asian CDMOs with cross-jurisdictional certification typically rank higher on this pillar than home-market-only competitors. Sponsors evaluating an Asian CDMO for a US or EU program should cross-check with the US region ranking and Europe region ranking — CDMOs appearing across regions have demonstrated multi-jurisdictional posture.

Recent US regulatory events affecting Asian CDMO selection (WuXi 1260H, BioSecure Act considerations)

Asian CDMOs — particularly Chinese-headquartered players — are subject to US regulatory events that affect sponsor risk assessment. The US Department of Defense's 1260H list (which added WuXi AppTec in June 2026) and the BioSecure Act (proposed federal legislation restricting federally-funded research and Medicare/Medicaid drug programs from working with named Chinese biotech companies) are both active considerations. CDMO Signal's platform does not encode US political risk into the Signal Score directly — the composite reflects regulatory quality, operations, financial stability, and capacity signals. Sponsors weighing an Asian CDMO for a US-supplying program should evaluate US regulatory risk separately as a distinct decision layer alongside the Signal Score-based capability assessment.

Plasmid DNA CDMOs — Frequently Asked Questions

Who are the top Plasmid DNA CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked Plasmid DNA CDMOs include Pharmaron Biologics, uBriGene Biosciences, CoJourney Inc.. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many Plasmid DNA CDMOs have FDA inspection records?

CDMO Signal tracks 1 Plasmid DNA CDMO with FDA inspection records and 0 EMA/MHRA GMP certificates across the group.

What should I look for in a plasmid DNA CDMO?

Confirm GMP grade and purity specs (supercoiled %, residual host DNA, endotoxin), fermentation scale and yield for your demand, realistic lead time, and a clean FDA and EMA/MHRA record.

Why is plasmid DNA supply often a bottleneck?

Plasmid is the starting material for viral vectors and mRNA, so a single GMP plasmid lot gates multiple downstream steps. Constrained GMP fermentation capacity and long queues make it a frequent critical-path item.

Related modalities

mRNA / LNP CDMOs Lentiviral Vector CDMOs AAV / Gene Therapy CDMOs

Other Modalities

AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC